...
首页> 外文期刊>American Journal of Kidney Diseases: The official journal of the National Kidney Foundation >Long-term outcomes in simultaneous kidney-pancreas transplant recipients with portal-enteric versus systemic-bladder drainage.
【24h】

Long-term outcomes in simultaneous kidney-pancreas transplant recipients with portal-enteric versus systemic-bladder drainage.

机译:在门-肠与全身膀胱引流同时进行的肾-胰腺移植受者的长期预后。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

We retrospectively reviewed long-term outcomes in simultaneous kidney-pancreas transplant (SKPT) recipients with portal-enteric (P-E) versus systemic-bladder (S-B) drainage. Forty-five patients were alive with functioning grafts 1 year after SKPT and were followed up for a minimum of 3 years (mean, 5.9 years), including 26 patients with P-E drainage and 19 patients with S-B drainage. Recipient demographic and transplant characteristics were similar between the two groups. In both groups, hospital admissions decreased significantly with increasing time after SKPT, although significantly fewer readmissions occurred in the first year in the P-E than the S-B group. The most common reason for readmission in both groups was infection, followed by miscellaneous, surgical, and immunologic morbidity. The incidence of readmission for dehydration was significantly less in the P-E group (P < 0.01). Mean systolic and diastolic blood pressures were similar between groups, although the number of antihypertensive medications was significantly less in the S-B group. Although fasting C-peptide levels were significantly greater in the S-B group, the two groups were similar with regard to carbohydrate (fasting serum glucose, hemoglobin A(1c)) and lipid (total cholesterol) metabolism. Renal and pancreas allograft functions were similar between the two groups. At 1 year post-SKPT, stabilization in most diabetic complications was reported. Four quality-of-life surveys that provided 29 scores were completed 6 to 24 months (mean, 18.5 months) after SKPT. Improved quality of life was reported in all but one of the scales, with many dimensions showing significant improvements. At 3 years after SKPT, no activity limitation was reported in 76% of patients with P-E drainage versus 53% with S-B drainage (P = 0.11). Five-year actual patient, kidney, and pancreas graft survival rates after P-E versus S-B drainage are 92% and 84%, 81% and 79%, and 88% and 74%, respectively (P = not significant). SKPT with P-E drainage is a safe and effective method to treat advanced diabetic nephropathy and is associated with decreasing morbidity, improving rehabilitation and quality of life, and stablizing metabolic function over time. The long-term prognosis after the first year is excellent and at least similar to the results achieved with S-B drainage.
机译:我们回顾性分析了同时行门-肠(P-E)与全身性膀胱(S-B)引流的肾-胰腺移植(SKPT)接受者的长期预后。 SKPT术后1年,有45例活着的移植物存活,并至少随访3年(平均5.9年),包括26例P-E引流患者和19例S-B引流患者。两组的接受者人口统计学和移植特征相似。在两组中,尽管SK-P组第一年的入院率明显低于S-B组,但入院时间随SKPT时间的增加而显着下降。两组中再次入院的最常见原因是感染,其次是其他,外科和免疫性疾病。 P-E组因脱水而再次入院的发生率显着降低(P <0.01)。两组之间的平均收缩压和舒张压相似,尽管在S-B组中降压药物的数量明显减少。尽管S-B组的空腹C肽水平显着更高,但两组在碳水化合物(空腹血清葡萄糖,血红蛋白A(1c))和脂质(总胆固醇)代谢方面相似。两组的肾脏和胰腺同种异体移植功能相似。据报道,SKPT治疗后1年,大多数糖尿病并发症均稳定下来。在SKPT之后的6到24个月(平均18.5个月)内完成了四项生活质量调查,这些调查提供了29分的评分。除了一种量表,据报告生活质量得到改善,许多方面都显示出明显的改善。 SKPT术后3年,P-E引流患者没有活动受限的报道,而S-B引流患者则为53%(P = 0.11)。 P-E与S-B引流后的五年实际患者,肾脏和胰腺移植物存活率分别为92%和84%,81%和79%,88%和74%(P =不显着)。带P-E引流的SKPT是治疗晚期糖尿病肾病的一种安全有效的方法,并且与降低发病率,改善康复和生活质量以及稳定新陈代谢功能相关。第一年后的长期预后非常好,至少与S-B引流的结果相似。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号